Cargando…

Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer

Novel therapeutic approaches against ovarian cancer (OC) are urgently needed because of its high rate of recurrence even after extensive surgery and multi-agent chemotherapy. We aimed to develop a novel anti-CD24 chimeric antigen receptor (CAR) as an immunotherapeutic approach against OC cells and c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klapdor, Rüdiger, Wang, Shuo, Morgan, Michael, Dörk, Thilo, Hacker, Ulrich, Hillemanns, Peter, Büning, Hildegard, Schambach, Axel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387114/ https://www.ncbi.nlm.nih.gov/pubmed/30717444 http://dx.doi.org/10.3390/ijms20030660

Ejemplares similares

NK Cell-Mediated Eradication of Ovarian Cancer Cells with a Novel Chimeric Antigen Receptor Directed against CD44
por: Klapdor, Rüdiger, et al.
Publicado: (2021)

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
por: Morgan, Michael A., et al.
Publicado: (2020)

Skeletal muscle-directed gene therapy: hijacking the fusogenic properties of muscle cells
por: Büning, Hildegard, et al.
Publicado: (2023)

Analyzing the Genotoxicity of Retroviral Vectors in Hematopoietic Cell Gene Therapy
por: Biasco, Luca, et al.
Publicado: (2017)

Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives
por: Hacker, Ulrich T., et al.
Publicado: (2020)

Gene therapy on the move
por: Kaufmann, Kerstin B, et al.
Publicado: (2013)

Engineering CAR-T Cells for Improved Function Against Solid Tumors
por: Morgan, Michael A., et al.
Publicado: (2018)

Pyroptotic and Necroptotic Cell Death in the Tumor Microenvironment and Their Potential to Stimulate Anti-Tumor Immune Responses
por: Scarpitta, Allan, et al.
Publicado: (2021)

Towards Novel Gene and Cell Therapy Approaches for Cervical Cancer
por: Polten, Robert, et al.
Publicado: (2022)

Tumor Organoid and Spheroid Models for Cervical Cancer
por: Kutle, Ivana, et al.
Publicado: (2023)

The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity
por: Zhang, Shangkun, et al.
Publicado: (2022)

Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
por: Schubert, Maria-Luisa, et al.
Publicado: (2023)

Gene therapy enters the pharma market: The short story of a long journey
por: Büning, Hildegard
Publicado: (2013)

Germline variation of Ribonuclease H2 genes in ovarian cancer patients
por: Polaczek, Rahel, et al.
Publicado: (2020)

Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123
por: Morgan, Michael A., et al.
Publicado: (2021)

Ex Vivo Generation of CAR Macrophages from Hematopoietic Stem and Progenitor Cells for Use in Cancer Therapy
por: Paasch, Daniela, et al.
Publicado: (2022)

The application of HER2 and CD47 CAR-macrophage in ovarian cancer
por: Chen, Yizhao, et al.
Publicado: (2023)

Adeno-Associated Viral Vectors at the Frontier between Tolerance and Immunity
por: Mingozzi, Federico, et al.
Publicado: (2015)

Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors
por: Büning, Hildegard, et al.
Publicado: (2019)

The hemogenic endothelium: a critical source for the generation of PSC-derived hematopoietic stem and progenitor cells
por: Lange, Lucas, et al.
Publicado: (2021)

Genetic Susceptibility to Endometrial Cancer: Risk Factors and Clinical Management
por: Dörk, Thilo, et al.
Publicado: (2020)

4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells
por: Roselli, Emiliano, et al.
Publicado: (2021)

Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell Metastasis
por: La, Huyen Thi, et al.
Publicado: (2021)

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
por: Korell, Felix, et al.
Publicado: (2023)

Association of preoperative cone biopsy with recurrences after radical hysterectomy
por: Klapdor, Rüdiger, et al.
Publicado: (2021)

Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer
por: Shu, Runzhe, et al.
Publicado: (2021)

Targeted Repair of p47-CGD in iPSCs by CRISPR/Cas9: Functional Correction without Cleavage in the Highly Homologous Pseudogenes
por: Klatt, Denise, et al.
Publicado: (2019)

Generation of an NFκB-Driven Alpharetroviral “All-in-One” Vector Construct as a Potent Tool for CAR NK Cell Therapy
por: Rudek, Loreen Sophie, et al.
Publicado: (2021)

Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial
por: Hacker, Ulrich T, et al.
Publicado: (2016)

Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity
por: Bartel, Melissa, et al.
Publicado: (2011)

Rational Design of Gene Therapy Vectors
por: Pan, Dao, et al.
Publicado: (2019)

A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma
por: Li, Hongwen, et al.
Publicado: (2023)

Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models
por: Sawaisorn, Piamsiri, et al.
Publicado: (2023)

Advantages and applications of CAR-expressing natural killer cells
por: Glienke, Wolfgang, et al.
Publicado: (2015)

TOPBP1 missense variant Arg309Cys and breast cancer in a German hospital-based case-control study
por: Blaut, Magda A, et al.
Publicado: (2010)

Light at the end of the tunnel of Corti
por: Hanlon, Kilian, et al.
Publicado: (2023)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

CAR models: next-generation CAR modifications for enhanced T-cell function
por: Abate-Daga, Daniel, et al.
Publicado: (2016)

Improved targeting of human CD4(+) T cells by nanobody-modified AAV2 gene therapy vectors
por: Hamann, Martin V., et al.
Publicado: (2021)

Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients
por: Laurent, Elisabeth, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j7696blt0jqanofl7g7empc2q4